3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Cholangiocarcinoma
6
Carcinoma, Transitional Cell
5
Acrocephalosyndactylia
5
Neoplasm Metastasis
3
Gastrointestinal Neoplasms
3
Breast Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Miscellaneous
1
Solid Tumor
1
Sarcoma
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Locally Advanced Unresectable Gastric Cancer
1
Liposarcoma
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Interventions
Imatinib Mesylate
27
regorafenib
8
nilotinib
6
Sunitinib
6
pazopanib
3
Temozolomide
3
Paclitaxel
3
Nivolumab
3
Ipilimumab
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
trametinib
2
spartalizumab
2
ripretinib
2
ponatinib
2
envafolimab
2
Specimen Handling
2
Sorafenib
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Laparoscopy
2
Dasatinib
2
Carboplatin
2
CTLA-4 Antigen
2
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
2
vatalanib
1
temsirolimus
1
rubitecan
1
romidepsin
1
perifosine
1
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gastrointestinal Stromal Tumors
×
pemigatinib
×
Clear all
NCT07434843
2026-05-22
PEMIGIST
Dana-Farber Cancer Institute
Phase 2
Recruiting
24 enrolled